These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Clinicopathological features and clinical outcomes associated with TP53 and BRAF Kim DW; Haydu LE; Joon AY; Bassett RL; Siroy AE; Tetzlaff MT; Routbort MJ; Amaria RN; Wargo JA; McQuade JL; Kemnade J; Hwu P; Woodman SE; Roszik J; Kim KB; Gershenwald JE; Lazar AJ; Davies MA Cancer; 2017 Apr; 123(8):1372-1381. PubMed ID: 27911979 [TBL] [Abstract][Full Text] [Related]
3. Mutations in the BRAF, NRAS, and C-KIT Genes of Patients Diagnosed with Melanoma in Colombia Population. Gutiérrez-Castañeda LD; Gamboa M; Nova JA; Pulido L; Tovar-Parra JD Biomed Res Int; 2020; 2020():2046947. PubMed ID: 32775409 [TBL] [Abstract][Full Text] [Related]
4. Clinical characteristics associated with BRAF, NRAS and KIT mutations in Japanese melanoma patients. Sakaizawa K; Ashida A; Uchiyama A; Ito T; Fujisawa Y; Ogata D; Matsushita S; Fujii K; Fukushima S; Shibayama Y; Hatta N; Takenouchi T; Uehara J; Okuyama R; Yamazaki N; Uhara H J Dermatol Sci; 2015 Oct; 80(1):33-7. PubMed ID: 26282084 [TBL] [Abstract][Full Text] [Related]
5. The molecular profile of metastatic melanoma in Australia. Lyle M; Haydu LE; Menzies AM; Thompson JF; Saw RP; Spillane AJ; Kefford RF; Mann GJ; Cooper WA; Yu B; Scolyer RA; O'Toole SA; Long GV Pathology; 2016 Feb; 48(2):188-93. PubMed ID: 27020391 [TBL] [Abstract][Full Text] [Related]
6. [ Spectrum of oncogene mutations is different in melanoma subtypes]. Mazurenko NN; Tsyganova IV; Lushnikova AA; Ponkratova DA; Anurova OA; Cheremushkin EA; Mikhailova IN; Demidov LV Mol Biol (Mosk); 2015; 49(6):1022-9. PubMed ID: 26710785 [TBL] [Abstract][Full Text] [Related]
7. Prevalence of BRAF, NRAS and c-KIT mutations in Slovenian patients with advanced melanoma. Moltara ME; Novakovic S; Boc M; Bucic M; Rebersek M; Zadnik V; Ocvirk J Radiol Oncol; 2018 Apr; 52(3):289-295. PubMed ID: 30210039 [TBL] [Abstract][Full Text] [Related]
8. Mutational dichotomy in desmoplastic malignant melanoma corroborated by multigene panel analysis. Jahn SW; Kashofer K; Halbwedl I; Winter G; El-Shabrawi-Caelen L; Mentzel T; Hoefler G; Liegl-Atzwanger B Mod Pathol; 2015 Jul; 28(7):895-903. PubMed ID: 25769001 [TBL] [Abstract][Full Text] [Related]
9. Clinicopathological characteristics and mutation profiling in primary cutaneous melanoma. Yaman B; Akalin T; Kandiloğlu G Am J Dermatopathol; 2015 May; 37(5):389-97. PubMed ID: 25357015 [TBL] [Abstract][Full Text] [Related]
10. Prognostic and predictive values of oncogenic BRAF, NRAS, c-KIT and MITF in cutaneous and mucous melanoma. Pracht M; Mogha A; Lespagnol A; Fautrel A; Mouchet N; Le Gall F; Paumier V; Lefeuvre-Plesse C; Rioux-Leclerc N; Mosser J; Oger E; Adamski H; Galibert MD; Lesimple T J Eur Acad Dermatol Venereol; 2015 Aug; 29(8):1530-8. PubMed ID: 25623140 [TBL] [Abstract][Full Text] [Related]
11. NRAS mutations are more prevalent than KIT mutations in melanoma of the female urogenital tract--a study of 24 cases from the Netherlands. van Engen-van Grunsven AC; Küsters-Vandevelde HV; De Hullu J; van Duijn LM; Rijntjes J; Bovée JV; Groenen PJ; Blokx WA Gynecol Oncol; 2014 Jul; 134(1):10-4. PubMed ID: 24802725 [TBL] [Abstract][Full Text] [Related]
12. [Characterization of genetic alterations in primary human melanomas carrying BRAF or NRAS mutation]. Lázár V Magy Onkol; 2013 Jun; 57(2):96-9. PubMed ID: 23795354 [TBL] [Abstract][Full Text] [Related]
13. Mutational profiling of acral melanomas in Korean populations. Shim JH; Shin HT; Park J; Park JH; Lee JH; Yang JM; Kim DH; Jang KT; Lee DY Exp Dermatol; 2017 Oct; 26(10):883-888. PubMed ID: 28191690 [TBL] [Abstract][Full Text] [Related]
14. The identification of patient-specific mutations reveals dual pathway activation in most patients with melanoma and activated receptor tyrosine kinases in BRAF/NRAS wild-type melanomas. Appenzeller S; Gesierich A; Thiem A; Hufnagel A; Jessen C; Kneitz H; Regensburger M; Schmidt C; Zirkenbach V; Bischler T; Schilling B; Siedel C; Goebeler ME; Houben R; Schrama D; Gehrig A; Rost S; Maurus K; Bargou R; Rosenwald A; Schartl M; Goebeler M; Meierjohann S Cancer; 2019 Feb; 125(4):586-600. PubMed ID: 30561760 [TBL] [Abstract][Full Text] [Related]
15. Targeted next-generation sequencing of Japanese patients with sinonasal mucosal melanomas identifies frequent NRAS and CTNNB1 mutations. Tsushima N; Kano S; Hatanaka KC; Suzuki T; Hamada S; Idogawa H; Nakamaru Y; Suzuki M; Hatanaka Y; Homma A Auris Nasus Larynx; 2024 Apr; 51(2):313-319. PubMed ID: 37953090 [TBL] [Abstract][Full Text] [Related]
16. Allele frequencies of BRAFV600 mutations in primary melanomas and matched metastases and their relevance for BRAF inhibitor therapy in metastatic melanoma. Satzger I; Marks L; Kerick M; Klages S; Berking C; Herbst R; Völker B; Schacht V; Timmermann B; Gutzmer R Oncotarget; 2015 Nov; 6(35):37895-905. PubMed ID: 26498143 [TBL] [Abstract][Full Text] [Related]
17. Malignant Melanoma of Vulva and Vagina: A Histomorphological Review and Mutation Analysis--A Single-Center Study. Rouzbahman M; Kamel-Reid S; Al Habeeb A; Butler M; Dodge J; Laframboise S; Murphy J; Rasty G; Ghazarian D J Low Genit Tract Dis; 2015 Oct; 19(4):350-3. PubMed ID: 26225944 [TBL] [Abstract][Full Text] [Related]
19. KIT, NRAS, BRAF and PTEN mutations in a sample of Swedish patients with acral lentiginous melanoma. Zebary A; Omholt K; Vassilaki I; Höiom V; Lindén D; Viberg L; Kanter-Lewensohn L; Johansson CH; Hansson J J Dermatol Sci; 2013 Dec; 72(3):284-9. PubMed ID: 23993026 [TBL] [Abstract][Full Text] [Related]
20. Oncogene abnormalities in a series of primary melanomas of the sinonasal tract: NRAS mutations and cyclin D1 amplification are more frequent than KIT or BRAF mutations. Chraybi M; Abd Alsamad I; Copie-Bergman C; Baia M; André J; Dumaz N; Ortonne N Hum Pathol; 2013 Sep; 44(9):1902-11. PubMed ID: 23664541 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]